BACKGROUND: Treatment with daunorubicin (DNR) in acute myeloid leukemia is moderately effective and associated with significant side effects, including cardiac toxicity. We recently developed a nanomicellar formulation of DNR that specifically targets acute myeloid leukemia stem cells. MATERIALS & METHODS: Pharmacokinetics analysis of free DNR, DNR in nanomicellar formulations was performed in Balb/c mice and Sprague-Dawley rats. Histochemical staining, caspase 3/7, troponin and creatine kinase MB isoenzyme were used to assess toxicity. RESULTS: Compared with free DNR, the nanomicellar formulations of DNR had less cardiotoxicity as evidenced by milder histopathological changes, lower caspase 3/7 activity in heart tissue (p = 0.002), lower plasma creatine kinase MB isoenzyme (p = 0.002) and troponin concentrations (p = 0.001) postinjection. The area under curve concentration of DNR in micelles increased by 31.9-fold in mice (p < 0.0001) and 22.0-fold higher in rats (p < 0.001). CONCLUSION: Leukemia stem cell-targeting micelles dramatically change the pharmacokinetics and reduce the cardiac toxicity of DNR, which may enable improved DNR-based treatment of acute myeloid leukemia.
BACKGROUND: Treatment with daunorubicin (DNR) in acute myeloid leukemia is moderately effective and associated with significant side effects, including cardiac toxicity. We recently developed a nanomicellar formulation of DNR that specifically targets acute myeloid leukemia stem cells. MATERIALS & METHODS: Pharmacokinetics analysis of free DNR, DNR in nanomicellar formulations was performed in Balb/c mice and Sprague-Dawley rats. Histochemical staining, caspase 3/7, troponin and creatine kinase MB isoenzyme were used to assess toxicity. RESULTS: Compared with free DNR, the nanomicellar formulations of DNR had less cardiotoxicity as evidenced by milder histopathological changes, lower caspase 3/7 activity in heart tissue (p = 0.002), lower plasma creatine kinase MB isoenzyme (p = 0.002) and troponin concentrations (p = 0.001) postinjection. The area under curve concentration of DNR in micelles increased by 31.9-fold in mice (p < 0.0001) and 22.0-fold higher in rats (p < 0.001). CONCLUSION:Leukemia stem cell-targeting micelles dramatically change the pharmacokinetics and reduce the cardiac toxicity of DNR, which may enable improved DNR-based treatment of acute myeloid leukemia.
Authors: Kai Xiao; Juntao Luo; Wiley L Fowler; Yuanpei Li; Joyce S Lee; Li Xing; R Holland Cheng; Li Wang; Kit S Lam Journal: Biomaterials Date: 2009-08-05 Impact factor: 12.479
Authors: Yuanpei Li; Kai Xiao; Juntao Luo; Wenwu Xiao; Joyce S Lee; Abby M Gonik; Jason Kato; Tiffany A Dong; Kit S Lam Journal: Biomaterials Date: 2011-06-11 Impact factor: 12.479
Authors: Charlotte F McDonagh; Alexandra Huhalov; Brian D Harms; Sharlene Adams; Violette Paragas; Shinji Oyama; Bo Zhang; Lia Luus; Ryan Overland; Stephanie Nguyen; Jinming Gu; Neeraj Kohli; Matt Wallace; Michael J Feldhaus; Arthur J Kudla; Birgit Schoeberl; Ulrik B Nielsen Journal: Mol Cancer Ther Date: 2012-01-16 Impact factor: 6.261
Authors: Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef Journal: N Engl J Med Date: 2009-09-24 Impact factor: 91.245
Authors: Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman Journal: N Engl J Med Date: 2009-09-24 Impact factor: 91.245
Authors: Anna van Rhenen; Guus A M S van Dongen; Angèle Kelder; Elwin J Rombouts; Nicole Feller; Bijan Moshaver; Marijke Stigter-van Walsum; Sonja Zweegman; Gert J Ossenkoppele; Gerrit Jan Schuurhuis Journal: Blood Date: 2007-07-03 Impact factor: 22.113